Stock Screener App

Frei -

Installieren

11.84

2.25% 0.26

after-market

Handel nachbörslich: 11.84

Avita Medical Inc (RCEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RCEL? Forum Prognose Aktiensplit

Avita Medical Inc Aktie (RCEL) Neueste Nachrichten

Liquidity Mapping Around (RCEL) Price Events - Stock Traders Daily

Avita Medical (RCEL) Slips 1.78% to $11.02 as Shares Drift Toward Lower SupportDark Pool Volume - siam.in

Avita Medical Notifies Cessation of 5,499 Unquoted Options Following Lapse of Conditions - kalkine.com.au

What Lies Ahead for Avita Medical (ASX:AVH) as Commercial Growth Progresses in 2026? - kalkine.com.au

Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Avita Medical Inc. Discloses CDI and Securities Statement for August 2026 - kalkine.com.au

Avita Medical Issues 25,213 Unquoted Options Expiring August 2036 Under Employee Incentive Scheme - kalkine.com.au

Avita Medical Issues 17,151 Common Stock Securities Following Multiple Option Conversions - Kalkine

Precision Trading with Avita Medical Inc. (RCEL) Risk Zones - Stock Traders Daily

564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc. - MarketBeat

Avita Medical Stock Price Forecast. Should You Buy RCEL? - StockInvest.us

RCEL stock gains on fresh price data while Avita Medical readies next steps - AD HOC NEWS

Gross margin % of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView

AVITA Medical to Present at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - kalkine.com.au

Net current asset value per share of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAM:51KB - TradingView

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference - Investing News Network

Avita Medical Inc.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

AVITA Medical to Showcase Leadership at Lake Street and Morgan Stanley Healthcare Conferences in September 2026 - Kalkine Media

A live webcast will carry AVITA Medical’s Sept. 16 conference discussion. - Stock Titan

AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Balance Sheet – HAM:51KB - TradingView

51KB Stock Price and Chart — HAM:51KB - TradingView

All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy - Yahoo Finance

Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $12 - Moomoo

RCEL | Avita Medical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative

Why Is AVITA Medical (ASX: AVH) Stock Up Over 100% in a Month? PermeaDerm Study Results Fuel the Rally - kalkine.com.au

AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL) - Seeking Alpha

Broker puts fresh buy ratings and tips 36% upside for these earnings results winners - The Motley Fool Australia

Avita Medical (RCEL) Stock Forum and Discussion - Moomoo

RCEL Maintained by TD Cowen -- Price Target Raised to $14.00 - GuruFocus

TD Cowen raises Avita Medical stock price target on PermeaDerm data - Investing.com Canada

RCEL Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus

AVITA Medical (NASDAQ:RCEL) Raises Full-Year Guidance on Spray-On Skin Adoption - Kalkine Media

Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft - Yahoo Finance

symbol__ Stock Quote Price and Forecast - CNN

BTIG raises Avita Medical stock price target on positive trial data - Investing.com Canada

TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $14 - Moomoo

THREE HEALTHCARE STOCKS on radar - kalkine.com.au

Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

AVITA Medical (ASX:AVH) Jumps 23.18% as Shares Extend a 67% One-Year Recovery - Kalkine

AVITA Medical (ASX:AVH) Soars 22.73% as Revenue Upgrade and Cash-Flow Target Reset the Conversation - Kalkine

AVITA Medical (ASX: AVH) Reports 70% Cost Advantage for PermeaDerm in Randomized Study - Kalkine

Avita Medical Says Clinical Study for Biosynthetic Wound Matrix Meets Primary Endpoint - marketscreener.com

AVITA Medical's PermeaDerm-I Study Reveals 70% Cost Savings Over Cadaveric Allograft with Equivalent Clinical Results - Kalkine Media

AVITA Medical Inc to Host Key Opinion Leader Webinar Transcript - GuruFocus

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes - Investing News Network

RCEL Looks 21.8% Undervalued on GF Value™ - GuruFocus

Avita Medical Says PermeaDerm Study Meets Primary Endpoint, Showing 70% Cost Reduction - marketscreener.com

AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com - Investing.com Canada

A wound matrix cut prep time 96% with outcomes comparable to cadaver grafts - Stock Titan

Avita Medical Raises Full Year 2026 Revenue Guidance - sekbernews.id

Avita Medical Raises Revenue Guidance and Targets Breakeven - sekbernews.id

AVITA Medical Inc Annual Shareholders Meeting Transcript - GuruFocus

AVITA Medical Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

RCEL Q2 2026 Earnings: Narrower Quarterly Loss Beats Estimates; Shares Slip 2%Earnings Quality Analysis - Vinanet

AVITA Medical, Inc. (RCEL) Shareholder/Analyst CallSlideshow (NASDAQ:RCEL) 2026-08-16 - Seeking Alpha

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% - MarketBeat

Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds - MarketBeat

RCEL Q2 2026 Earnings: EPS Beat of 14.5% Overshadowed by a 2% Stock DeclineEarnings Expansion Phase - Vinanet

RCEL Q2 2026 Earnings: Narrower Loss Beats Estimates by 14.5%, but Shares Slip 2%Core Business Growth - careplusvn.com

RCEL Q2 2026 Earnings: Loss Narrower Than Expected, Delivering 14.5% EPS SurpriseSpecial Dividend Alert - Vinanet

RCEL Q2 2026 Earnings: Narrower Loss Beats Expectations as Shares Edge LowerEstimate Revision Count - Vinanet

AVITA Medical Inc (RCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

ZBH

$91.04

1.51%

STE

$208.93

0.08%

PHG

$24.96

1.67%

GEHC

$66.63

0.38%

DXCM

$86.62

0.97%

EW

$86.29

0.65%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters